Close Lucintel Chat
Didn't Find What You're Looking for?
Call us at +1972 636 5056 or write at helpdesk@Lucintel.com
Ask an Expert Provide Custom Requirements Download Sample Report Search Available Reports
  • helpdesk@Lucintel.com
  • |
  • Call Lucintel +1 972 636 5056
  • |
  • Login
  • |
  • Register
  • |
  • Search
  • |
'
...

The Impact of COVID-19 is included in Pharmacogenomic Market. Buy it today to get an advantage.

Request the impact of COVID-19 on your product or industry


The future of the pharmacogenomics market looks promising with opportunities in cardiovascular diseases, infectious diseases, oncology, neurological diseases, psychiatry, and pain management. The global pharmacogenomic market is expected to grow with a CAGR of 8%-10% from 2020 to 2025. The major drivers for this market are increasing prevalence of several infectious and non-infectious diseases, rising usage in drug discovery processes, increasing demand for personalized drugs, and growing awareness of the benefits associated with pharmacogenomics.

A total of XX figures / charts and XX tables are provided in this more than 150-pages report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global pharmacogenomics market report, please download the report brochure.




 
 
In this market, polymerase chain reaction (PCR) is the largest technology of pharmacogenomics, whereas cardiovascular disease is the largest application. Growth in various segments of the pharmacogenomics market are given below:






 
The study includes trends and forecast for the global pharmacogenomics market by technology, application, end user, and region as follows:
By Technology [Value ($ Million) shipment analysis for 2014 – 2025]:
Sequencing
Polymerase Chain Reaction
Gel Electrophoresis
Mass Spectrometry
Microarray
Others 
 
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Cardiovascular Diseases
Infectious Diseases
Oncology
Neurological Diseases
Psychiatry
Pain Management
Others
 
By End User [Value ($ Million) shipment analysis for 2014 – 2025]: 
Hospitals & Clinics
Research Institutions and Academic Institutes
Others
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North America
United States
Canada 
Mexico
Europe
United Kingdom
Spain
Germany
France
Asia Pacific
China
India
Japan
The Rest of the World 
Brazil
 
Some of the pharmacogenomics companies profiled in this report include Affymetrix, AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Bayer, Merck, GlaxoSmithKline, Johnson & Johnson, Myriad Genetics, and Pathway Genomics Corporation.
Lucintel forecasts that polymerase chain reaction will remain the largest technology segment over the forecast period due to its irreplaceability in terms of use for the amplification of a small segment of DNA.
Within this market, hospitals and clinics will remain the largest end user segment over the forecast period due to better infrastructure and technological edge over other medical centers and the presence of highly skilled medical professionals and patients.
North America will remain the largest region over the forecast period due to increasing usage of pharmacogenomics in the development of more potent as well as personalized medicines and high awareness among physicians and drug developers of the benefits of pharmacogenomics, such as increased reliability and reduced side effects.


 
Features of the Global Pharmacogenomics Market
 
  • Market Size Estimates: Global pharmacogenomics market size estimation in terms of value ($M) shipment.
  • Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
  • Segmentation Analysis: Global pharmacogenomics market size by various segments, such as technology, application, and end user in terms of value.
  • Regional Analysis: Global pharmacogenomics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different technology, application, end user, and region for the global pharmacogenomics market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global pharmacogenomics market.
  • Analysis of competitive intensity of the industry based on Porter’s Five Forces model.



 
This report answers following key questions
 
Q.1 What are some of the most promising potential, high-growth opportunities for the global pharmacogenomics market by technology (sequencing, polymerase chain reaction, gel electrophoresis, mass spectrometry, microarray, and others), application (cardiovascular diseases, infectious diseases, oncology, neurological diseases, psychiatry, pain management, and others), and end user (hospitals & clinics, research institutions and academic institutes, and others), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global pharmacogenomics market?
Q.5 What are the business risks and threats to the global pharmacogenomics market?
Q.6 What are the emerging trends in this pharmacogenomics market and the reasons behind them?
Q.7 What are some changing demands of customers in this pharmacogenomics market?
Q.8 What are the new developments in this pharmacogenomics market? Which companies are leading these developments?
Q.9 Who are the major players in this pharmacogenomics market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this pharmacogenomics market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global pharmacogenomics market?

 




Report Scope


Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates)		 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Technology (Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others), Application (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others), and End User (Hospitals & Clinics, Research Institutions and Academic Institutes, and Others)

Regional Scope

North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, an Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost

Table of Contents
1. Executive Summary
2. Market Background and Classifications
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2014 to 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Pharmacogenomics Market Trends and Forecast
3.3: Global Pharmacogenomics Market by Technology
3.3.1: Sequencing 
3.3.2: Polymerase Chain Reaction 
3.3.3: Gel Electrophoresis 
3.3.4: Mass Spectrometry 
3.3.5: Microarray 
3.3.6: Others 
3.4: Global Pharmacogenomics Market by Application
3.4.1: Cardiovascular Diseases 
3.4.2: Infectious Diseases 
3.4.3: Oncology 
3.4.4: Neurological Diseases 
3.4.5: Psychiatry 
3.4.6: Pain Management 
3.4.7: Others
3.5: Global Pharmacogenomics Market by End User
3.5.1: Hospitals & Clinics 
3.5.2: Research Institutions and Academic Institutes 
3.5.3: Others
4. Market Trends and Forecast Analysis by Region
4.1: Global Pharmacogenomics Market by Region
4.2: North American Pharmacogenomics Market
4.2.1: Market by Technology: Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others
4.2.2: Market by Application: Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others 
4.2.3: Market by End User: Hospitals & Clinics, Research Institutions and Academic Institutes, and Others
4.2.4: The United States Pharmacogenomics Market
4.2.5: The Canadian Pharmacogenomics Market
4.2.6: The Mexican Pharmacogenomics Market
4.3: European Pharmacogenomics Market
4.3.1: Market by Technology: Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others
4.3.2: Market by Application: Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others 
4.3.3: Market by End User: Hospitals & Clinics, Research Institutions and Academic Institutes, and Others
4.3.4: The United Kingdom Pharmacogenomics Market
4.3.5: The Spanish Pharmacogenomics Market
4.3.6: The German Pharmacogenomics Market
4.3.7: The French Pharmacogenomics Market
4.4: APAC Pharmacogenomics Market
4.4.1: Market by Technology: Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others
4.4.2: Market by Application: Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others 
4.4.3: Market by End User: Hospitals & Clinics, Research Institutions and Academic Institutes, and Others
4.4.4: The Chinese Pharmacogenomics Market
4.4.5: The Indian Pharmacogenomics Market
4.4.6: The Japanese Pharmacogenomics Market
4.5: ROW Pharmacogenomics Market
4.5.1: Market by Technology: Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, and Others
4.5.2: Market by Application: Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Psychiatry, Pain Management, and Others 
4.5.3: Market by End User: Hospitals & Clinics, Research Institutions and Academic Institutes, and Others
4.5.4: Brazilian Pharmacogenomics Market
5. Competitor Analysis
5.1: Market Share Analysis
5.2: Product Portfolio Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. Cost Structure Analysis
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. Growth Opportunities and Strategic Analysis
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Pharmacogenomics Market by Technology
7.1.2: Growth Opportunities for the Global Pharmacogenomics Market by Application
7.1.3: Growth Opportunities for the Global Pharmacogenomics Market by End User
7.1.4: Growth Opportunities for the Global Pharmacogenomics Market by Region
7.2: Emerging Trends in the Global Pharmacogenomics Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Pharmacogenomics Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Pharmacogenomics  Market
7.3.4: Certification and Licensing
8. Company Profiles of Leading Players
8.1: Affymetrix 
8.2: AstraZeneca 
8.3: Bristol-Myers Squibb Company 
8.4: F. Hoffmann-La Roche 
8.5: Bayer 
8.6: Merck 
8.7: GlaxoSmithKline 
8.8: Johnson & Johnson 
8.9: Myriad Genetics 
8.10: Pathway Genomics Corporation 
 
.

Buy full report or by chapter as follows

Price by License Type:
[-] Hide Chapter Details
[Chapter Number] [Chapter Name] [Chapter Number Of Pages] [Chapter Price]
Title/Chapter Name Pages Price
Full Report: Pharmacogenomic Market: Trends, Forecast and Competitive Analysis Full Report $ 4,850
150 - page report
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
  • In-depth interviews of the major players in this market
  • Detailed secondary research from competitors’ financial statements and published data 
  • Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
  • A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
 
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process. 
 

Please sign in below to get report brochure - Pharmacogenomic Market.

At Lucintel, we respect your privacy and maintain the confidentiality of information / data provided by you
(Please enter your corporate email. * These fields are mandatory )
Have an Account / Returning Visitors?

Follow us on